374 related articles for article (PubMed ID: 16187775)
1. Metabolic effects associated with atypical antipsychotic treatment in the developmentally disabled.
McKee JR; Bodfish JW; Mahorney SL; Heeth WL; Ball MP
J Clin Psychiatry; 2005 Sep; 66(9):1161-8. PubMed ID: 16187775
[TBL] [Abstract][Full Text] [Related]
2. The effects of novel antipsychotics on glucose and lipid levels.
Wirshing DA; Boyd JA; Meng LR; Ballon JS; Marder SR; Wirshing WC
J Clin Psychiatry; 2002 Oct; 63(10):856-65. PubMed ID: 12416594
[TBL] [Abstract][Full Text] [Related]
3. A retrospective comparison of weight, lipid, and glucose changes between risperidone- and olanzapine-treated inpatients: metabolic outcomes after 1 year.
Meyer JM
J Clin Psychiatry; 2002 May; 63(5):425-33. PubMed ID: 12019668
[TBL] [Abstract][Full Text] [Related]
4. Comparison of longer-term safety and effectiveness of 4 atypical antipsychotics in patients over age 40: a trial using equipoise-stratified randomization.
Jin H; Shih PA; Golshan S; Mudaliar S; Henry R; Glorioso DK; Arndt S; Kraemer HC; Jeste DV
J Clin Psychiatry; 2013 Jan; 74(1):10-8. PubMed ID: 23218100
[TBL] [Abstract][Full Text] [Related]
5. A 12-week randomized clinical trial to evaluate metabolic changes in drug-naive, first-episode psychosis patients treated with haloperidol, olanzapine, or risperidone.
Perez-Iglesias R; Crespo-Facorro B; Amado JA; Garcia-Unzueta MT; Ramirez-Bonilla ML; Gonzalez-Blanch C; Martinez-Garcia O; Vazquez-Barquero JL
J Clin Psychiatry; 2007 Nov; 68(11):1733-40. PubMed ID: 18052567
[TBL] [Abstract][Full Text] [Related]
6. Atypical antipsychotics for psychosis in adolescents.
Kumar A; Datta SS; Wright SD; Furtado VA; Russell PS
Cochrane Database Syst Rev; 2013 Oct; (10):CD009582. PubMed ID: 24129841
[TBL] [Abstract][Full Text] [Related]
7. Weight gain and antipsychotic medication: differences between antipsychotic-free and treatment periods.
Simpson MM; Goetz RR; Devlin MJ; Goetz SA; Walsh BT
J Clin Psychiatry; 2001 Sep; 62(9):694-700. PubMed ID: 11681765
[TBL] [Abstract][Full Text] [Related]
8. Adjunctive effects of aripiprazole on metabolic profiles: comparison of patients treated with olanzapine to patients treated with other atypical antipsychotic drugs.
Wang LJ; Ree SC; Huang YS; Hsiao CC; Chen CK
Prog Neuropsychopharmacol Biol Psychiatry; 2013 Jan; 40():260-6. PubMed ID: 23085073
[TBL] [Abstract][Full Text] [Related]
9. Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis.
Henderson DC; Cagliero E; Copeland PM; Borba CP; Evins AE; Hayden D; Weber MT; Anderson EJ; Allison DB; Daley TB; Schoenfeld D; Goff DC
Arch Gen Psychiatry; 2005 Jan; 62(1):19-28. PubMed ID: 15630069
[TBL] [Abstract][Full Text] [Related]
10. Effects of typical and atypical antipsychotics on glucose-insulin homeostasis and lipid metabolism in first-episode schizophrenia.
Wu RR; Zhao JP; Liu ZN; Zhai JG; Guo XF; Guo WB; Tang JS
Psychopharmacology (Berl); 2006 Jul; 186(4):572-8. PubMed ID: 16601995
[TBL] [Abstract][Full Text] [Related]
11. Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics.
Lindenmayer JP; Czobor P; Volavka J; Citrome L; Sheitman B; McEvoy JP; Cooper TB; Chakos M; Lieberman JA
Am J Psychiatry; 2003 Feb; 160(2):290-6. PubMed ID: 12562575
[TBL] [Abstract][Full Text] [Related]
12. Atypical antipsychotic medication improves aggression, but not self-injurious behaviour, in adults with intellectual disabilities.
Ruedrich SL; Swales TP; Rossvanes C; Diana L; Arkadiev V; Lim K
J Intellect Disabil Res; 2008 Feb; 52(Pt 2):132-40. PubMed ID: 18197952
[TBL] [Abstract][Full Text] [Related]
13. Development of an atherogenic metabolic risk factor profile associated with the use of atypical antipsychotics.
Alméras N; Després JP; Villeneuve J; Demers MF; Roy MA; Cadrin C; Mottard JP; Bouchard RH
J Clin Psychiatry; 2004 Apr; 65(4):557-64. PubMed ID: 15119921
[TBL] [Abstract][Full Text] [Related]
14. [Therapy with antipsychotic drugs as a risk factor for diabetes in schizophrenia: a case-control study].
Rubio G; Gómez-de-la-Cámara A; Ledesma F; Burón JA; Rodríguez-Morales A; Martínez-Junquera G;
Med Clin (Barc); 2006 Apr; 126(12):441-4. PubMed ID: 16620729
[TBL] [Abstract][Full Text] [Related]
15. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review.
Newcomer JW
CNS Drugs; 2005; 19 Suppl 1():1-93. PubMed ID: 15998156
[TBL] [Abstract][Full Text] [Related]
16. [Metabolic side effects of risperidone in early onset schizophrenia].
Goeb JL; Marco S; Duhamel A; Kechid G; Bordet R; Thomas P; Delion P; Jardri R
Encephale; 2010 Jun; 36(3):242-52. PubMed ID: 20620267
[TBL] [Abstract][Full Text] [Related]
17. Effects of olanzapine and risperidone on metabolic factors in children and adolescents: a retrospective evaluation.
Khan RA; Mican LM; Suehs BT
J Psychiatr Pract; 2009 Jul; 15(4):320-8. PubMed ID: 19625888
[TBL] [Abstract][Full Text] [Related]
18. Metabolic risk with second-generation antipsychotic treatment: a double-blind randomized 8-week trial of risperidone and olanzapine.
Kelly DL; Conley RR; Love RC; Morrison JA; McMahon RP
Ann Clin Psychiatry; 2008; 20(2):71-8. PubMed ID: 18568578
[TBL] [Abstract][Full Text] [Related]
19. Quetiapine versus other atypical antipsychotics for schizophrenia.
Asmal L; Flegar SJ; Wang J; Rummel-Kluge C; Komossa K; Leucht S
Cochrane Database Syst Rev; 2013 Nov; (11):CD006625. PubMed ID: 24249315
[TBL] [Abstract][Full Text] [Related]
20. A multicenter, randomized, double-blind study of the effects of aripiprazole in overweight subjects with schizophrenia or schizoaffective disorder switched from olanzapine.
Newcomer JW; Campos JA; Marcus RN; Breder C; Berman RM; Kerselaers W; L'italien GJ; Nys M; Carson WH; McQuade RD
J Clin Psychiatry; 2008 Jul; 69(7):1046-56. PubMed ID: 18605811
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]